aBLA Filing Intelligence & Biosimilar Opportunity

Piasky

Crovalimab-Akkz

Immunomodulators

Intravenous Infusion

Nemluvio is an injectable antibody for adults suffering from debilitating itch in prurigo nodularis or moderate-to-severe atopic dermatitis. It blocks the IL‑31 receptor to reduce itching and improve skin healing, offering relief within 48 hours.

Approval Date

20-Jun-24

Data Exclusivity Expiry

20-Jun-28

Market Exclusivity Expiry

20-Jun-36

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.5675

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

148

2027

229

2028

277

2029

332

2030

382

2031

425

2032

468

Molecule profile

Details & specifications

Molecule

Crovalimab-Akkz

Innovator

GENENTECH

Dosage Form

Intravenous Infusion

Strength

340 mg/2 mL

Therapeutic Category

Immunomodulators

Usage

To treat paroxysmal nocturnal hemoglobinuria

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.